ArticleFrontiers in endocrinology2026
Factors associated with type 1 gastric neuroendocrine tumor occurrence in autoimmune atrophic gastritis: insights from a real-world cohort.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autoimmune gastritis (AIG) is characterized by chronic inflammation and represents a key step in the multistage precancerous process of the stomach. Patients with AIG are at increased risk of developing type I gastric neuroendocrine tumors (T1gNETs), but clinical and histological associated factors still remain incompletely defined. Aim: To evaluate the occurrence of T1gNETs in our AIG patients cohort and to identify clinical, biochemical, and histological factors associated with tumor development. Methods: Retrospective analysis of histologically confirmed AIG followed at Humanitas Research Hospital (from January 2020 to February 2025). Clinical, biochemical, and histological variables were extracted from a dedicated database. Associations between T1gNETs incidence and risk factors (smoking, BMI, gastrin,chromogranin- CgA levels, histology, clinical presentation) were tested using chi-square, Spearman and Mann-Whitney tests, with bootstrap-derived confidence intervals for effect sizes. Results: Among 175 AIG patients, 28 (16%) were diagnosed with T1gNETs. ECL cell hyperplasia emerged as the strongest histological factor associated with T1gNETs (82.1 vs 55.8; p= 0.0109, OR = 3.65). Conversely, dyspeptic symptoms showed a significant inverse correlation with tumor occurrence (21.4% vs 43.5%; p=0.035, OR = 0.35), suggesting that T1gNETs often develop in asymptomatic patients. No significant predictive value was found for smoking, alcohol, BMI, severe hypergastrinemia/CgA (>3x ULN) levels or degree of corpus atrophy, although a trend was observed for corpus metaplasia. Conclusions: Patients with AIG face significantly elevated occurrence of T1gNETs compared with the general population, with percentage being in line with recent studies. ECL hyperplasia was found as a factor associated with NET development, according to literature, confirming that the chronic stimulation of a cell with the ability to proliferate, results in tumors formation. Most patients with T1gNETs were asymptomatic and no correlation was found with smoking, alcohol and BMI. As a future perspective, these findings, even though preliminary, may help in the risk stratification of patients for more personalized endoscopic surveillance protocols, but further data are warranted to better standardize their use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.